Exscientia Announced Three Abstracts To Be Presented At The EORTC-NCI-AACR Symposium 2024
Portfolio Pulse from Benzinga Newsdesk
Exscientia announced the presentation of three abstracts at the EORTC-NCI-AACR Symposium 2024, highlighting the potential of MALT1 and BTK inhibitors in B-cell malignancies, efficacy of '539 in AML models, and PD biomarkers for LSD1 inhibitor treatment.
October 09, 2024 | 11:20 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Exscientia is set to present promising research at the EORTC-NCI-AACR Symposium 2024, including potential treatments for B-cell malignancies and AML, which could positively impact its stock price.
The announcement of Exscientia's presentations at a major symposium highlights significant advancements in their research, particularly in cancer treatment. This could lead to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90